- Home
- OPP vs CABA Comparison
OPP vs CABA Comparison
Compare OPP & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPP | CABA |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.2M | 212.7M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | OPP | CABA |
|---|---|---|
| Price | $7.87 | $3.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $14.57 |
| AVG Volume (30 Days) | 108.0K | ★ 3.8M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 14.41% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.26 | $0.99 |
| 52 Week High | $8.83 | $3.67 |
Technical Indicators
Market Signals| Indicator | OPP | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 45.51 | 67.87 |
| Support Level | $7.78 | $2.04 |
| Resistance Level | $8.01 | $3.34 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 44.44 | 75.39 |
Price Performance
Historical ComparisonAbout OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.
RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.